The GLP-1 drug market is already worth over $50 billion annually. Every major player in it requires an injection.
That is the gap ASC30 is targeting.
Ascletis Pharma (HKEX: 1672) announced on April 26, 2026 that it has completed enrollment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 receptor agonist, for the treatment of type 2 diabetes. One hundred participants across multiple US sites. Topline data expected in Q3 2026.
ASC30 is already in Phase II for obesity following positive results announced in December 2025. Diabetes is the second indication. The company expects to file for FDA clearance to begin Phase III obesity trials by the end of Q3 2026.
Why oral matters so much in this market
Semaglutide, sold as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly, are injectable drugs administered weekly. They have transformed the treatment landscape for obesity and type 2 diabetes, generating combined annual revenues that have reshaped both companies’ market capitalizations. Ozempic alone generated over $14 billion in sales in 2024.
Novo Nordisk has an oral version of semaglutide, Rybelsus, approved for diabetes at doses up to 14mg. It requires specific administration conditions, taken with a small amount of water 30 minutes before food, and delivers meaningfully lower bioavailability than the injectable form. The weight loss results at approved oral doses have been less pronounced than weekly injectable semaglutide.
A once-daily oral tablet that delivers efficacy comparable to injectable GLP-1 drugs without the administration complexity would represent a fundamental shift in how these medications reach patients. Needle aversion, injection site reactions, and the practical burden of weekly self-injection are real barriers to treatment uptake, particularly in populations with lower healthcare engagement.
ASC30 is described by Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist. The biased agonism distinction matters pharmacologically. Most GLP-1R agonists activate multiple signaling pathways simultaneously, which contributes to both efficacy and the nausea and gastrointestinal side effects that cause many patients to discontinue treatment. A biased agonist selectively activates specific downstream pathways, with the goal of preserving the metabolic benefits while reducing the side effect burden that limits tolerability.
What the Phase II diabetes study is measuring
The study is randomized, double-blind, and placebo-controlled across three dose levels: 40mg, 60mg, and 80mg. The primary endpoint is mean change from baseline in HbA1c, the standard long-term blood glucose control marker, over 13 weeks. Secondary endpoints include fasting blood glucose, body weight change, and safety and tolerability.
HbA1c reduction is the established benchmark for diabetes drug efficacy. Approved GLP-1 drugs typically achieve reductions of 1 to 2 percentage points from baseline, which is clinically meaningful for most patients with type 2 diabetes. If ASC30 achieves comparable HbA1c reductions in an oral formulation with acceptable tolerability, it establishes the case for progression to Phase III.
The body weight secondary endpoint is strategically important. Type 2 diabetes and obesity are deeply linked conditions, and a drug that addresses both glycemic control and weight simultaneously is more commercially compelling than one that addresses only blood glucose.
According to the International Diabetes Federation’s 2025 Atlas, approximately 537 million adults worldwide live with diabetes, with type 2 diabetes accounting for roughly 90% of cases. Global spending on diabetes medications exceeds $60 billion annually. An oral GLP-1 therapy with strong efficacy and tolerability would enter a market of enormous scale.
The competitive landscape and where ASC30 sits
Pfizer, Roche, Eli Lilly, and several other major pharmaceutical companies are developing oral small molecule GLP-1 agonists. The class is one of the most competitive in drug development. Pfizer’s danuglipron showed modest weight loss in Phase II and the company has explored twice-daily dosing. Roche’s CT-996 has shown early promise in Phase I data.
Ascletis is a smaller Hong Kong-listed biotech competing against significantly better-resourced players. Its advantage, if ASC30 delivers on its Phase II obesity data and the diabetes study performs, is first-mover positioning in oral biased GLP-1R agonism and the specific tolerability profile that biased agonism is designed to produce.
Phase II results are not Phase III results. Enrollment completion is a process milestone, not an efficacy signal. The Q3 2026 topline data will determine whether ASC30’s diabetes program has legs.
Sources
Editorial disclosure
This article is based on a press release issued by Ascletis Pharma Inc. and has been independently rewritten and editorially expanded. It covers completion of enrollment in a US Phase II clinical study of ASC30 for type 2 diabetes. Ascletis Pharma trades on the Hong Kong Stock Exchange under 1672.HK. ASC30 is an investigational drug that has not received regulatory approval for any indication. Phase II enrollment completion is a process milestone and does not indicate efficacy or safety outcomes. Topline Phase II data is expected in Q3 2026 and results may not support progression to Phase III. Clinical stage biotechnology investments carry significant risk. This article does not constitute medical or investment advice. Market context is sourced from the International Diabetes Federation. Commentary reflects the author’s own assessment. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
